Atypical haemolytic uraemic syndrome and mutations in complement regulator genes View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-09-28

AUTHORS

Marie-Agnès Dragon-Durey, Véronique Frémeaux-Bacchi

ABSTRACT

Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) disorder characterised by the association of haemolytic anaemia, thrombocytopenia and acute renal failure. Atypical forms (non-related to shigatoxin) may be familial or sporadic, with frequent recurrences and most of them lead to end stage renal failure. During the last years, different groups have demonstrated genetic predisposition of atypical HUS involving complement components factor H (FH), CD46 [or membrane co-factor protein (MCP)] and factor I. These three proteins are involved in the regulation of the alternative pathway of the complement system. Several series have reported mutations in the FH gene (called HF1) in between 10 and 22% of atypical HUS patients. At this time, four pedigrees corresponding to 13 cases have been reported with an MCP mutation and four cases with a sporadic disease presented factor I mutation. Whereas FH mutations were reported in both familial and sporadic forms of HUS, CD46 mutations were restricted to familial HUS, and factor I mutations were only observed in cases of sporadic HUS. We speculate that the penetrance of the disease may be variable regarding the identified susceptibility factors. Recently, the analysis of single nucleotide polymorphisms in both HF1 and MCP in three large cohorts of HUS patients identified significant association between atypical HUS and HF1 and MCP particular alleles. All these results, together with the finding of anti-FH antibodies in some atypical HUS patients, strongly suggest that an abnormality in the regulation of the alternative pathway participates in the patho-physiological mechanisms of atypical HUS. The recent progress made in the determination of susceptibility factors for atypical HUS has permitted the development of new diagnostic tests and may eventually lead to new specific treatments to block the pathological process. More... »

PAGES

359-374

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2

DOI

http://dx.doi.org/10.1007/s00281-005-0003-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034722638

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16189652


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Autoantibodies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement Factor H", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement Factor I", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Complement System Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemolytic-Uremic Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heterozygote", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Homozygote", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Cofactor Protein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Purpura, Thrombotic Thrombocytopenic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service d'Immunologie Biologique, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.414093.b", 
          "name": [
            "Service d'Immunologie Biologique, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dragon-Durey", 
        "givenName": "Marie-Agn\u00e8s", 
        "id": "sg:person.0706660410.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706660410.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM U255, Institut de recherche des Cordeliers, 15 rue de l'Ecole de M\u00e9decine, 75006, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "Service d'Immunologie Biologique, H\u00f4pital Europ\u00e9en Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France", 
            "INSERM U255, Institut de recherche des Cordeliers, 15 rue de l'Ecole de M\u00e9decine, 75006, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fr\u00e9meaux-Bacchi", 
        "givenName": "V\u00e9ronique", 
        "id": "sg:person.0776460004.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776460004.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00862598", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000380400", 
          "https://doi.org/10.1007/bf00862598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00467-004-1526-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011641665", 
          "https://doi.org/10.1007/s00467-004-1526-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-09-28", 
    "datePublishedReg": "2005-09-28", 
    "description": "Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) disorder characterised by the association of haemolytic anaemia, thrombocytopenia and acute renal failure. Atypical forms (non-related to shigatoxin) may be familial or sporadic, with frequent recurrences and most of them lead to end stage renal failure. During the last years, different groups have demonstrated genetic predisposition of atypical HUS involving complement components factor H (FH), CD46 [or membrane co-factor protein (MCP)] and factor I. These three proteins are involved in the regulation of the alternative pathway of the complement system. Several series have reported mutations in the FH gene (called HF1) in between 10 and 22% of atypical HUS patients. At this time, four pedigrees corresponding to 13 cases have been reported with an MCP mutation and four cases with a sporadic disease presented factor I mutation. Whereas FH mutations were reported in both familial and sporadic forms of HUS, CD46 mutations were restricted to familial HUS, and factor I mutations were only observed in cases of sporadic HUS. We speculate that the penetrance of the disease may be variable regarding the identified susceptibility factors. Recently, the analysis of single nucleotide polymorphisms in both HF1 and MCP in three large cohorts of HUS patients identified significant association between atypical HUS and HF1 and MCP particular alleles. All these results, together with the finding of anti-FH antibodies in some atypical HUS patients, strongly suggest that an abnormality in the regulation of the alternative pathway participates in the patho-physiological mechanisms of atypical HUS. The recent progress made in the determination of susceptibility factors for atypical HUS has permitted the development of new diagnostic tests and may eventually lead to new specific treatments to block the pathological process.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00281-005-0003-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1038741", 
        "issn": [
          "1863-2297", 
          "1863-2300"
        ], 
        "name": "Seminars in Immunopathology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "keywords": [
      "atypical haemolytic uraemic syndrome", 
      "haemolytic uraemic syndrome", 
      "factor I mutation", 
      "atypical HUS patients", 
      "HUS patients", 
      "renal failure", 
      "uraemic syndrome", 
      "end-stage renal failure", 
      "susceptibility factors", 
      "acute renal failure", 
      "stage renal failure", 
      "patho-physiological mechanisms", 
      "factor H", 
      "sporadic haemolytic uraemic syndrome", 
      "anti-FH antibodies", 
      "new diagnostic tests", 
      "thrombotic microangiopathy disorders", 
      "new specific treatments", 
      "I mutations", 
      "MCP mutations", 
      "frequent recurrence", 
      "large cohort", 
      "genetic predisposition", 
      "specific treatment", 
      "haemolytic anaemia", 
      "CD46 mutation", 
      "sporadic forms", 
      "complement regulator genes", 
      "sporadic disease", 
      "significant association", 
      "FH mutations", 
      "atypical forms", 
      "complement system", 
      "FH gene", 
      "patients", 
      "diagnostic tests", 
      "alternative pathway", 
      "pathological processes", 
      "single nucleotide polymorphisms", 
      "syndrome", 
      "disease", 
      "nucleotide polymorphisms", 
      "factor I.", 
      "association", 
      "mutations", 
      "thrombocytopenia", 
      "failure", 
      "anemia", 
      "recurrence", 
      "cohort", 
      "particular alleles", 
      "pathway", 
      "abnormalities", 
      "different groups", 
      "cases", 
      "antibodies", 
      "CD46", 
      "disorders", 
      "predisposition", 
      "regulator gene", 
      "factors", 
      "treatment", 
      "genes", 
      "penetrance", 
      "regulation", 
      "last years", 
      "polymorphism", 
      "group", 
      "years", 
      "findings", 
      "alleles", 
      "protein", 
      "MCP", 
      "test", 
      "pedigree", 
      "mechanism", 
      "HF1", 
      "i.", 
      "recent progress", 
      "development", 
      "form", 
      "time", 
      "analysis", 
      "series", 
      "progress", 
      "results", 
      "determination", 
      "system", 
      "process"
    ], 
    "name": "Atypical haemolytic uraemic syndrome and mutations in complement regulator genes", 
    "pagination": "359-374", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034722638"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00281-005-0003-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16189652"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00281-005-0003-2", 
      "https://app.dimensions.ai/details/publication/pub.1034722638"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_408.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00281-005-0003-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00281-005-0003-2'


 

This table displays all metadata directly associated to this object as RDF triples.

217 TRIPLES      21 PREDICATES      128 URIs      118 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00281-005-0003-2 schema:about N55e67db389264d0fbaabc7fc84d4f348
2 N56471fe1b8be46ce86f0488da956aa4f
3 N72129e17ccae45d38650ee0998dc1454
4 N85b2e6c264ae4661b17e8524a4191122
5 N867044707a8a441ea3c0d66395889e53
6 N8b177ec3ca3145f488a98b99e236d7fb
7 N93deb2fc635649358bf7e08843b34bf2
8 N9c84898c747d41f09eba1925af50d498
9 N9f9faf73788241b2a01a0755a51c3542
10 Ne54a788aa2d14d11bec11cc0e7010d34
11 Nf520fd5d58c14f08b4c3001bd3ea9857
12 Nf61a821333f94ceca09ffbe538d0cba9
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author Nabb76ab1b4db451c8baef3b8d11ea706
16 schema:citation sg:pub.10.1007/bf00862598
17 sg:pub.10.1007/s00467-004-1526-9
18 schema:datePublished 2005-09-28
19 schema:datePublishedReg 2005-09-28
20 schema:description Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) disorder characterised by the association of haemolytic anaemia, thrombocytopenia and acute renal failure. Atypical forms (non-related to shigatoxin) may be familial or sporadic, with frequent recurrences and most of them lead to end stage renal failure. During the last years, different groups have demonstrated genetic predisposition of atypical HUS involving complement components factor H (FH), CD46 [or membrane co-factor protein (MCP)] and factor I. These three proteins are involved in the regulation of the alternative pathway of the complement system. Several series have reported mutations in the FH gene (called HF1) in between 10 and 22% of atypical HUS patients. At this time, four pedigrees corresponding to 13 cases have been reported with an MCP mutation and four cases with a sporadic disease presented factor I mutation. Whereas FH mutations were reported in both familial and sporadic forms of HUS, CD46 mutations were restricted to familial HUS, and factor I mutations were only observed in cases of sporadic HUS. We speculate that the penetrance of the disease may be variable regarding the identified susceptibility factors. Recently, the analysis of single nucleotide polymorphisms in both HF1 and MCP in three large cohorts of HUS patients identified significant association between atypical HUS and HF1 and MCP particular alleles. All these results, together with the finding of anti-FH antibodies in some atypical HUS patients, strongly suggest that an abnormality in the regulation of the alternative pathway participates in the patho-physiological mechanisms of atypical HUS. The recent progress made in the determination of susceptibility factors for atypical HUS has permitted the development of new diagnostic tests and may eventually lead to new specific treatments to block the pathological process.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf N9ab9139816f54aa3b26565e459f4bca9
24 Nf245399013404f7393bdf63958171123
25 sg:journal.1038741
26 schema:keywords CD46
27 CD46 mutation
28 FH gene
29 FH mutations
30 HF1
31 HUS patients
32 I mutations
33 MCP
34 MCP mutations
35 abnormalities
36 acute renal failure
37 alleles
38 alternative pathway
39 analysis
40 anemia
41 anti-FH antibodies
42 antibodies
43 association
44 atypical HUS patients
45 atypical forms
46 atypical haemolytic uraemic syndrome
47 cases
48 cohort
49 complement regulator genes
50 complement system
51 determination
52 development
53 diagnostic tests
54 different groups
55 disease
56 disorders
57 end-stage renal failure
58 factor H
59 factor I mutation
60 factor I.
61 factors
62 failure
63 findings
64 form
65 frequent recurrence
66 genes
67 genetic predisposition
68 group
69 haemolytic anaemia
70 haemolytic uraemic syndrome
71 i.
72 large cohort
73 last years
74 mechanism
75 mutations
76 new diagnostic tests
77 new specific treatments
78 nucleotide polymorphisms
79 particular alleles
80 patho-physiological mechanisms
81 pathological processes
82 pathway
83 patients
84 pedigree
85 penetrance
86 polymorphism
87 predisposition
88 process
89 progress
90 protein
91 recent progress
92 recurrence
93 regulation
94 regulator gene
95 renal failure
96 results
97 series
98 significant association
99 single nucleotide polymorphisms
100 specific treatment
101 sporadic disease
102 sporadic forms
103 sporadic haemolytic uraemic syndrome
104 stage renal failure
105 susceptibility factors
106 syndrome
107 system
108 test
109 thrombocytopenia
110 thrombotic microangiopathy disorders
111 time
112 treatment
113 uraemic syndrome
114 years
115 schema:name Atypical haemolytic uraemic syndrome and mutations in complement regulator genes
116 schema:pagination 359-374
117 schema:productId N169e7bbc185f4a5681f9e9968fc8bc0c
118 N7f4c324e9951498eb97e6ae6cea49229
119 Nf0f07c2ae5fb4942b70358507d704eb8
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034722638
121 https://doi.org/10.1007/s00281-005-0003-2
122 schema:sdDatePublished 2022-08-04T16:55
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher N07f6f78bbd034f9795fc3e324dff3e87
125 schema:url https://doi.org/10.1007/s00281-005-0003-2
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N07f6f78bbd034f9795fc3e324dff3e87 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 N169e7bbc185f4a5681f9e9968fc8bc0c schema:name doi
132 schema:value 10.1007/s00281-005-0003-2
133 rdf:type schema:PropertyValue
134 N55e67db389264d0fbaabc7fc84d4f348 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Complement Factor I
136 rdf:type schema:DefinedTerm
137 N56471fe1b8be46ce86f0488da956aa4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Complement Factor H
139 rdf:type schema:DefinedTerm
140 N72129e17ccae45d38650ee0998dc1454 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Hemolytic-Uremic Syndrome
142 rdf:type schema:DefinedTerm
143 N7f4c324e9951498eb97e6ae6cea49229 schema:name dimensions_id
144 schema:value pub.1034722638
145 rdf:type schema:PropertyValue
146 N85b2e6c264ae4661b17e8524a4191122 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Purpura, Thrombotic Thrombocytopenic
148 rdf:type schema:DefinedTerm
149 N867044707a8a441ea3c0d66395889e53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Homozygote
151 rdf:type schema:DefinedTerm
152 N8b177ec3ca3145f488a98b99e236d7fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Membrane Cofactor Protein
154 rdf:type schema:DefinedTerm
155 N93deb2fc635649358bf7e08843b34bf2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Models, Immunological
157 rdf:type schema:DefinedTerm
158 N9ab9139816f54aa3b26565e459f4bca9 schema:volumeNumber 27
159 rdf:type schema:PublicationVolume
160 N9c0d2eac202f49c0b26355303702ab9f rdf:first sg:person.0776460004.20
161 rdf:rest rdf:nil
162 N9c84898c747d41f09eba1925af50d498 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Mutation
164 rdf:type schema:DefinedTerm
165 N9f9faf73788241b2a01a0755a51c3542 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Heterozygote
167 rdf:type schema:DefinedTerm
168 Nabb76ab1b4db451c8baef3b8d11ea706 rdf:first sg:person.0706660410.14
169 rdf:rest N9c0d2eac202f49c0b26355303702ab9f
170 Ne54a788aa2d14d11bec11cc0e7010d34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Complement System Proteins
172 rdf:type schema:DefinedTerm
173 Nf0f07c2ae5fb4942b70358507d704eb8 schema:name pubmed_id
174 schema:value 16189652
175 rdf:type schema:PropertyValue
176 Nf245399013404f7393bdf63958171123 schema:issueNumber 3
177 rdf:type schema:PublicationIssue
178 Nf520fd5d58c14f08b4c3001bd3ea9857 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Humans
180 rdf:type schema:DefinedTerm
181 Nf61a821333f94ceca09ffbe538d0cba9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Autoantibodies
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
188 schema:name Clinical Sciences
189 rdf:type schema:DefinedTerm
190 sg:journal.1038741 schema:issn 1863-2297
191 1863-2300
192 schema:name Seminars in Immunopathology
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.0706660410.14 schema:affiliation grid-institutes:grid.414093.b
196 schema:familyName Dragon-Durey
197 schema:givenName Marie-Agnès
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706660410.14
199 rdf:type schema:Person
200 sg:person.0776460004.20 schema:affiliation grid-institutes:grid.7429.8
201 schema:familyName Frémeaux-Bacchi
202 schema:givenName Véronique
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776460004.20
204 rdf:type schema:Person
205 sg:pub.10.1007/bf00862598 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000380400
206 https://doi.org/10.1007/bf00862598
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s00467-004-1526-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011641665
209 https://doi.org/10.1007/s00467-004-1526-9
210 rdf:type schema:CreativeWork
211 grid-institutes:grid.414093.b schema:alternateName Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France
212 schema:name Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France
213 rdf:type schema:Organization
214 grid-institutes:grid.7429.8 schema:alternateName INSERM U255, Institut de recherche des Cordeliers, 15 rue de l'Ecole de Médecine, 75006, Paris, France
215 schema:name INSERM U255, Institut de recherche des Cordeliers, 15 rue de l'Ecole de Médecine, 75006, Paris, France
216 Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, AP-HP, 20 rue Leblanc, 75015, Paris, France
217 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...